Viking Therapeutics, Inc. (VKTX) Q4 2023 Earnings Results

Viking Therapeutics Misses on EPS, Stock Down 0.53%

Viking Therapeutics reported a loss of $0.25 per share, which was in line with expectations, but did not provide any revenue figures. The stock reacted negatively, declining by 0.53%, likely due to the lack of guidance and clarity on future performance. Investors may be cautious given the absence of specific financial targets or updates.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.25	N/A	+0.00%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Neutral

Management maintained a neutral tone during the call, focusing on current operations without offering specific future guidance. There were no notable comments on revenue or earnings expectations.

Management did not provide specific insights on revenue performance.

No guidance updates were shared during the call.

Viking Therapeutics Misses on EPS, Stock Down 0.53%

Key numbers

Management commentary

Viking Therapeutics, Inc.

More earnings this week

Viking Therapeutics Misses on EPS, Stock Down 0.53%

Key numbers

Management commentary